Abstracts tagged "pregnancy and systemic lupus erythematosus (SLE)"

Abstract Number: 602 • 2012 ACR/ARHP Annual Meeting
Sexual and Reproductive Health Counseling Among Adolescents with Systemic Lupus Erythematosus
Xue Tian¹, Murray H. Passo², Janice D. Key³, Thomas C. Hulsey⁴ and Natasha M. Ruth¹, ¹Pediatric Rheumatology, The Medical University of South Carolina, Charleston, SC, ²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ³Adolescent Medicine, The Medical University of South Carolina, Charleston, SC, ⁴Pediatrics, The Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that is known to target young adults, especially women of child-bearing age. Although it is well-accepted…
Abstract Number: 2263 • 2012 ACR/ARHP Annual Meeting
The Association Between Prior Pregnancy Morbidity and Cardiovascular Events in Women with Systemic Lupus Erythematosus
Megan E. B. Clowse¹, Eliza F. Chakarvarty², Jill P. Buyon³ and Gerald McGwin Jr.⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Adverse pregnancy outcomes have been associated with increased cardiovascular disease in healthy women. We hypothesized that women with SLE and a history of adverse…
Abstract Number: 1648 • 2012 ACR/ARHP Annual Meeting
Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss
Michelle Petri¹, Anil Mankee², Ehtisham Akhter², Hong Fang¹ and Laurence S. Magder³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Multiple factors, including proteinuria, antiphospholipid syndrome, thrombocytopenia and hypertension, are predictive of pregnancy loss in SLE. In the PROMISSE study of mediators of pregnancy…
Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting
Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy
Jill P. Buyon¹, Aanam Aslam², Marta M. Guerra², Michael D. Lockshin³, Carl A. Laskin⁴, Ware Branch⁵, Lisa R. Sammaritano⁶, Michelle Petri⁷, Joan T. Merrill⁸, Allen D. Sawitzke⁹ and Jane E. Salmon⁶, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
Abstract Number: 649 • 2012 ACR/ARHP Annual Meeting
Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Emil P. Nashi³, Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁵, Meggan C. Mackay⁶ and Cynthia Aranow⁷, ¹McGill University Health Centre, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Recent experimental evidence suggests that anti-DNA antibodies, cross-reacting with brainstem neuronal receptors, induce apoptosis and cause a marked preferential loss of female foetuses in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].